Skip to main content
Clinical Trials/NCT01388413
NCT01388413
Completed
Phase 4

A Randomized, Multicenter, Parallel Group Study to Evaluate Safety and Efficacy of a Weekly Oral Cyclic Antibiotic Programme in the Prevention of Urinary Tract Infection on Neurological Bladder

University Hospital, Tours4 sites in 1 country45 target enrollmentAugust 1, 2011

Overview

Phase
Phase 4
Intervention
Weekly Oral Cyclic Antibiotic programme
Conditions
Neurogenic Bladder
Sponsor
University Hospital, Tours
Enrollment
45
Locations
4
Primary Endpoint
Number of symptomatic UTIs
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

Symptomatic urinary tract infections (UTIs) are one of the main causes of morbidity and the main cause of re-hospitalization in subjects with neurogenic bladder. Long-term antibiotic therapy increases the risk of multi-resistant bacterial infections, without reducing the rate of symptomatic UTIs. Our non-comparative preliminary study has shown that Weekly Oral Cyclic Antibiotic Programme (single, weekly dose of antibiotic X on even weeks, and antibiotic Y on odd weeks) seem to drastically reduce both the number of symptomatic UTIs and the number of hospitalizations in patients with neurogenic bladder, without affecting bacterial ecology.

The objective of this study is to validate this preliminary work with a large-scale randomized, parallel-group, multicenter study.

Registry
clinicaltrials.gov
Start Date
August 1, 2011
End Date
February 1, 2017
Last Updated
4 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • subject over 18 years of age
  • having a neurogenic bladder with automatic catheter and pharmacologic disconnection of the detrusor muscle
  • having at least 4 symptomatic UTIs per year with bacterial sensitivity to the chosen antibiotics
  • having given full consent to participate in the study
  • being the recipient of social security benefits

Exclusion Criteria

  • known allergy or hypersensitivity to useful antibiotics (to which the bacterium or bacteria are sensitive) or to one of their components
  • other contraindication in the administering of useful antibiotics
  • urinary volume flow \>500 ml during automatic catheter
  • different urinary drainage method than automatic catheter
  • occurrence of stones in the urinary tract
  • infection due to endo urinary material (urinary prosthesis, ureteral stent)
  • creatinine clearance \<60 ml/min
  • patient under guardianship
  • women who are pregnant, nursing, or who may become pregnant

Arms & Interventions

Weekly Oral Cyclic Antibiotic programme

Intervention: Weekly Oral Cyclic Antibiotic programme

Outcomes

Primary Outcomes

Number of symptomatic UTIs

Time Frame: During the 6-month follow-up

Symptomatic UTIs are defined by the presence of infection or reinfection by the same bacteria, in combination with the presence of definite clinical signs of infection (autonomous hyper-reflexivity, spasticity, leakage, contractures, pyuria, fever, shivers).

Secondary Outcomes

  • The number of feverish UTIs(During the 6-month follow-up)
  • The emergence of multi-resistant bacteria in urine (cultures), digestive bacteria (anal swabs), oro-pharynx bacteria (nasal swabs), and semi-quantitative research of multi-resistant bacteria in the stool.(During the 6-month follow-up)
  • The duration of UTI-related hospitalizations(During the 6-month follow-up)
  • The global antibiotic consumption.(During the 6-month follow-up)
  • The number of urine culture negative(During the 6-month follow-up)
  • the quality of life(During the 6-month follow-up)
  • The number of hospitalizations(During the 6-month follow-up.)
  • The tolerance level to the Weekly Oral Cyclic Antibiotic Programme, measured by any adverse effects to antibiotics(During the 6-month follow-up.)

Study Sites (4)

Loading locations...

Similar Trials